These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

422 related articles for article (PubMed ID: 33710717)

  • 1. Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes.
    Dahl K; Brooks A; Almazedi F; Hoff ST; Boschini C; Baekdal TA
    Diabetes Obes Metab; 2021 Jul; 23(7):1594-1603. PubMed ID: 33710717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity.
    Hjerpsted JB; Flint A; Brooks A; Axelsen MB; Kvist T; Blundell J
    Diabetes Obes Metab; 2018 Mar; 20(3):610-619. PubMed ID: 28941314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial.
    Hermansen K; Bækdal TA; Düring M; Pietraszek A; Mortensen LS; Jørgensen H; Flint A
    Diabetes Obes Metab; 2013 Nov; 15(11):1040-8. PubMed ID: 23683069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity.
    Friedrichsen M; Breitschaft A; Tadayon S; Wizert A; Skovgaard D
    Diabetes Obes Metab; 2021 Mar; 23(3):754-762. PubMed ID: 33269530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients.
    Flint A; Kapitza C; Hindsberger C; Zdravkovic M
    Adv Ther; 2011 Mar; 28(3):213-26. PubMed ID: 21340616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of oral semaglutide on energy intake, food preference, appetite, control of eating and body weight in subjects with type 2 diabetes.
    Gibbons C; Blundell J; Tetens Hoff S; Dahl K; Bauer R; Baekdal T
    Diabetes Obes Metab; 2021 Feb; 23(2):581-588. PubMed ID: 33184979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase 1, randomized, double-blind, placebo-controlled trial investigating the pharmacokinetics, pharmacodynamics, safety and tolerability of oral semaglutide in healthy Chinese subjects.
    Xie P; Abildlund MT; Bækdal TA; He X; Lyauk YK; Patted URH; Ning Z; Shi A
    Diabetes Obes Metab; 2024 Aug; 26(8):3068-3077. PubMed ID: 38808476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
    Ahrén B; Masmiquel L; Kumar H; Sargin M; Karsbøl JD; Jacobsen SH; Chow F
    Lancet Diabetes Endocrinol; 2017 May; 5(5):341-354. PubMed ID: 28385659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial.
    Kapitza C; Dahl K; Jacobsen JB; Axelsen MB; Flint A
    Diabetologia; 2017 Aug; 60(8):1390-1399. PubMed ID: 28526920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Sustained Treatment With Lixisenatide on Gastric Emptying and Postprandial Glucose Metabolism in Type 2 Diabetes: A Randomized Controlled Trial.
    Rayner CK; Watson LE; Phillips LK; Lange K; Bound MJ; Grivell J; Wu T; Jones KL; Horowitz M; Ferrannini E; Tricò D; Frascerra S; Mari A; Natali A
    Diabetes Care; 2020 Aug; 43(8):1813-1821. PubMed ID: 32471908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study.
    DeFronzo RA; Okerson T; Viswanathan P; Guan X; Holcombe JH; MacConell L
    Curr Med Res Opin; 2008 Oct; 24(10):2943-52. PubMed ID: 18786299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.
    Pratley R; Amod A; Hoff ST; Kadowaki T; Lingvay I; Nauck M; Pedersen KB; Saugstrup T; Meier JJ;
    Lancet; 2019 Jul; 394(10192):39-50. PubMed ID: 31186120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lixisenatide Reduces Chylomicron Triacylglycerol by Increased Clearance.
    Whyte MB; Shojaee-Moradie F; Sharaf SE; Jackson NC; Fielding B; Hovorka R; Mendis J; Russell-Jones D; Umpleby AM
    J Clin Endocrinol Metab; 2019 Feb; 104(2):359-368. PubMed ID: 30215735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Administration of resveratrol for 5 wk has no effect on glucagon-like peptide 1 secretion, gastric emptying, or glycemic control in type 2 diabetes: a randomized controlled trial.
    Thazhath SS; Wu T; Bound MJ; Checklin HL; Standfield S; Jones KL; Horowitz M; Rayner CK
    Am J Clin Nutr; 2016 Jan; 103(1):66-70. PubMed ID: 26607942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response to Dahl et al.: Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes.
    Horowitz M; Rayner CK; Marathe CS; Wu T; Umapathysivam M; Jones KL
    Diabetes Obes Metab; 2021 Oct; 23(10):2411-2413. PubMed ID: 34169640
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of lixisenatide once daily on gastric emptying in type 2 diabetes--relationship to postprandial glycemia.
    Lorenz M; Pfeiffer C; Steinsträsser A; Becker RH; Rütten H; Ruus P; Horowitz M
    Regul Pept; 2013 Aug; 185():1-8. PubMed ID: 23665027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial.
    Mosenzon O; Blicher TM; Rosenlund S; Eriksson JW; Heller S; Hels OH; Pratley R; Sathyapalan T; Desouza C;
    Lancet Diabetes Endocrinol; 2019 Jul; 7(7):515-527. PubMed ID: 31189517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial.
    Zinman B; Bhosekar V; Busch R; Holst I; Ludvik B; Thielke D; Thrasher J; Woo V; Philis-Tsimikas A
    Lancet Diabetes Endocrinol; 2019 May; 7(5):356-367. PubMed ID: 30833170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response to the letter from Horowitz et al. to the Editor relating to the publication 'Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes' by Dahl et al.
    Dahl K; Baekdal TA
    Diabetes Obes Metab; 2021 Oct; 23(10):2414-2416. PubMed ID: 34212484
    [No Abstract]   [Full Text] [Related]  

  • 20. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes.
    Matikainen N; Mänttäri S; Schweizer A; Ulvestad A; Mills D; Dunning BE; Foley JE; Taskinen MR
    Diabetologia; 2006 Sep; 49(9):2049-57. PubMed ID: 16816950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.